Voyager Therapeutics (VYGR) Revenue (2015 - 2026)

Voyager Therapeutics (VYGR) has 12 years of Revenue data on file, last reported at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 59.94% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $36.5 million (down 45.46% YoY), and the FY2025 full-year result was $40.4 million, down 49.53% from the prior year.
• Revenue retreated to $2.6 million in Q1 2026, from $15.4 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $150.5 million in Q1 2023 to a low of -$1.5 million in Q4 2022.
• A 5-year average of $24.4 million and a median of $6.5 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue slumped 105.52% in 2022 and jumped 22769.3% in 2023, its largest moves.
• Tracing VYGR's Revenue over 5 years: stood at -$1.5 million in 2022, then surged by 5913.42% to $90.1 million in 2023, then tumbled by 93.01% to $6.3 million in 2024, then surged by 143.99% to $15.4 million in 2025, then slumped by 83.13% to $2.6 million in 2026.
• Business Quant data shows VYGR's Revenue at $2.6 million in Q1 2026, $15.4 million in Q4 2025, and $13.4 million in Q3 2025.